公开(公告)号：US20210292418A1

公开(公告)日：2021-09-23

申请号：US17204604

申请日：2021-03-17

Applicant: GENMAB A/S

Inventor： Louise KOOPMAN ,  Patrick ENGELBERTS ,  Dennis VERZIJL ,  Edward N. VAN DEN BRINK ,  Rik RADEMAKER ,  Sieto BOSGRA ,  Frederikke L. EGEROD ,  David SATIJN ,  Esther C. W. BREIJ

IPC: C07K16/28 ,  A61P35/00

Abstract: The present invention relates to antibodies binding to B7H4, including bispecific antibodies binding to B7H4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

公开(公告)号：US20180326084A1

公开(公告)日：2018-11-15

申请号：US15742818

申请日：2016-07-08

Applicant: GENMAB A/S

Inventor： Julia BOSHUIZEN ,  Kirstine JACOBSEN ,  Esther BREIJ ,  Louise KOOPMAN ,  David SATIJN ,  Edward VAN DEN BRINK ,  Dennis VERZIJL ,  Rob DE JONG ,  Riemke VAN DIJKHUIZEN RADERSMA ,  Daniel PEEPER ,  Henrik Jørn DITZEL ,  Paul PARREN

IPC: A61K47/68 ,  C07K16/28 ,  A61P35/00 ,  A61K45/06 ,  A61K39/00

CPC classification number: A61K47/6803 ,  A61K39/001102 ,  A61K45/06 ,  A61K47/6801 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6855 ,  A61K47/6857 ,  A61K47/6869 ,  A61K2039/505 ,  A61P35/00 ,  C07K16/2863 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2317/92

Abstract: The present disclosure relates to antibody-drug conjugates (ADCs) binding to human AXL for therapeutic use, particularly for treatment of resistant or refractory cancers.

公开(公告)号：US20180194845A1

公开(公告)日：2018-07-12

申请号：US15832366

申请日：2017-12-05

Applicant: GENMAB A/S

Inventor： Bart DE GOEIJ ,  Simone DE HAIJ ,  Thilo RIEDL ,  Rene HOET ,  Ole BAADSGAARD ,  Jan VAN DE WINKEL ,  David SATIJN ,  Paul PARREN ,  Aran Frank LABRIJN ,  Joyce MEESTERS ,  Janine SCHUURMAN ,  Edward N. VAN DEN BRINK

IPC: C07K16/28 ,  C07K16/32 ,  A61K39/00

CPC classification number: C07K16/2863 ,  A61K2039/505 ,  C07K16/2809 ,  C07K16/32 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/526 ,  C07K2317/528 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2317/92

Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

公开(公告)号：US20180179286A1

公开(公告)日：2018-06-28

申请号：US15832421

申请日：2017-12-05

Applicant: GENMAB A/S

Inventor： Bart DE GOEIJ ,  Simone DE HAIJ ,  Thilo RIEDL ,  Rene HOET ,  Ole BAADSGAARD ,  Jan VAN DE WINKEL ,  David SATIJN ,  Paul PARREN ,  Aran Frank LABRIJN ,  Joyce MEESTERS ,  Janine SCHUURMAN ,  Edward N. VAN DEN BRINK

IPC: C07K16/28 ,  C07K16/32 ,  A61K39/00

CPC classification number: C07K16/2863 ,  A61K2039/505 ,  C07K16/2809 ,  C07K16/32 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/526 ,  C07K2317/528 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2317/92

Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

公开(公告)号：US20170355767A1

公开(公告)日：2017-12-14

申请号：US15541594

申请日：2016-01-08

Applicant: GENMAB A/S

Inventor： Patrick ENGELBERTS ,  Esther BREIJ ,  Rik RADEMAKER ,  Isil ALTINTAS ,  David SATIJN ,  Sandra VERPLOEGEN ,  Riemke VAN DIJKHUIZEN RADERSMA ,  Edward VAN DEN BRINK ,  Janine SCHUURMAN ,  Paul PARREN

IPC: C07K16/28 ,  A61K39/395

CPC classification number: C07K16/2809 ,  A61K39/39558 ,  A61K2039/505 ,  C07K16/2887 ,  C07K16/30 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/567 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/75 ,  C07K2317/90 ,  C07K2317/92 ,  C07K2317/94

Abstract: Bispecific antibodies directed to CD3 and CD20 and uses of such bispecific antibodies, in particular use thereof in the treatment of diseases in which specific targeting and T cell-mediated killing of cells that express CD20 is desired.

公开(公告)号：US20170136130A1

公开(公告)日：2017-05-18

申请号：US15277626

申请日：2016-09-27

Applicant: GENMAB A/S

Inventor： David SATIJN ,  Sandra VERPLOEGEN ,  Wim BLEEKER ,  Steen LISBY ,  Jan VAN DE WINKEL ,  Patrick VAN BERKEL ,  Paul PARREN

IPC: A61K39/00 ,  C07K16/36 ,  A61K45/06

CPC classification number: C07K16/30 ,  A61K45/06 ,  A61K47/6817 ,  A61K47/6849 ,  C07K16/36 ,  C07K2317/21 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92

Abstract: Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapeutic and diagnostic methods for using the antibodies and antibody drug conjugates.

公开(公告)号：US20240392032A1

公开(公告)日：2024-11-28

申请号：US18617483

申请日：2024-03-26

Applicant: Genmab A/S

Inventor： David SATIJN ,  Esther C.W. Breij ,  Bart E.C.G. De Goeij ,  Kristel Kemper ,  Patrick Engelberts ,  Edward N. Van Den Brink ,  Rik Rademaker ,  Dennis Verzijl ,  Sjeng Horbach ,  Paul Parren

IPC: C07K16/30 ,  A61K39/00 ,  A61K47/68 ,  A61P35/00 ,  C12N15/79

Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

公开(公告)号：US20240294661A1

公开(公告)日：2024-09-05

申请号：US18526959

申请日：2023-12-01

Applicant: Genmab A/S

Inventor： David SATIJN ,  Sandra VERPLOEGEN ,  Wim BLEEKER ,  Steen LISBY ,  Jan VAN DE WINKEL ,  Patrick VAN BERKEL ,  Paul PARREN

IPC: C07K16/30 ,  A61K45/06 ,  A61K47/68 ,  C07K16/36

CPC classification number: C07K16/30 ,  A61K45/06 ,  A61K47/6817 ,  A61K47/6849 ,  C07K16/36 ,  C07K2317/21 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92

Abstract: Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapeutic and diagnostic methods for using the antibodies and antibody drug conjugates.

公开(公告)号：US20240091352A1

公开(公告)日：2024-03-21

申请号：US18175894

申请日：2023-02-28

Applicant: GENMAB A/S

Inventor： Esther BREIJ ,  David SATIJN ,  Edward Norbert VAN DEN BRINK ,  Dennis VERZIJL ,  Rob N. DE JONG ,  Paul PARREN ,  Riemke VAN DIJKHUIZEN RADERSMA

IPC: A61K39/395 ,  A61K47/68 ,  C07K16/28 ,  C07K16/30

CPC classification number: A61K39/39558 ,  A61K47/6801 ,  A61K47/6855 ,  A61K47/6857 ,  A61K47/6869 ,  C07K16/2863 ,  C07K16/3061 ,  A61K2039/505

Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.

公开(公告)号：US20230365714A1

公开(公告)日：2023-11-16

申请号：US18029472

申请日：2021-10-01

Applicant: GENMAB A/S

Inventor： Louise Koopman ,  Patrick ENGELBERTS ,  David SATIJN ,  Jan Hermen DANNENBERG

IPC: C07K16/46 ,  A61P35/00

CPC classification number: C07K16/468 ,  A61P35/00 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/24 ,  C07K2317/35 ,  C07K2317/92

Abstract: The present invention relates to antibodies binding to ROR2, including bispecific antibodies binding to ROR2 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.